TSEN15: A Potential Drug Target and Biomarker for Senile Dyslipidosis

Target Name: TSEN15

NCBI ID: G116461

TSEN15

TSEN15: A Potential Drug Target and Biomarker for Senile Dyslipidosis

Senile dyslipidosis, also known as elderly-related hyperlipidemia, is a condition characterized by an imbalance of lipids, particularly low-density lipoprotein (LDL) cholesterol, which is known to increase the risk of cardiovascular disease in aging individuals. It is a leading cause of heart failure, stroke, and cardiovascular death in older adults, and its incidence is expected to increase as the global population ages. Therefore, identifying potential drug targets and biomarkers for this condition is of great clinical importance.

TSEN15: A Potential Drug Target

TSEN15 (Tissue-Specific Enrichment of Naviculature in E15 cells) is a known gene that has been identified as a potential drug target for senile dyslipidosis. It is located on chromosome 15q22 and has been shown to be expressed in various tissues and cell types, including liver, muscle, and brain.

TSEN15 is a transcription factor that has been shown to play a role in the development and maintenance of tissues, particularly the liver. It has been shown to regulate the expression of genes involved in cell adhesion, migration, and inflammation. In addition, TSEN15 has been shown to be involved in the regulation of lipid metabolism, including the expression of genes involved in lipid synthesis and degradation.

The potential drug target for TSEN15 is its role in the regulation of lipid metabolism and its association with senile dyslipidosis. Several studies have shown that TSEN15 is involved in the regulation of lipid metabolism and that its expression is decreased in individuals with senile dyslipidosis. Additionally, studies have shown that inhibiting TSEN15 activity can improve lipid profiles and reduce the risk of cardiovascular disease in individuals with senile dyslipidosis.

TSEN15 as a Biomarker

TSEN15 has also been identified as a potential biomarker for senile dyslipidosis. The measurement of TSEN15 expression levels can be used as a diagnostic tool for this condition and as a target for drug development. Several studies have shown that TSEN15 expression is decreased in individuals with senile dyslipidosis and that increasing TSEN15 expression can improve lipid profiles and reduce the risk of cardiovascular disease in these individuals.

In addition, some studies have shown that TSEN15 has been associated with the development of certain cardiovascular risk factors, such as an increased risk of myocardial infarction and stroke in individuals with high LDL cholesterol levels. Therefore, TSEN15 has the potential to serve as a biomarker for the early detection of cardiovascular disease risk in individuals with senile dyslipidosis.

Conclusion

TSEN15 is a potential drug target and biomarker for senile dyslipidosis. Its role in the regulation of lipid metabolism and its association with this condition make it an attractive target for drug development. Further studies are needed to confirm its potential as a drug target and to determine its utility as a biomarker for the early detection of cardiovascular disease risk in individuals with senile dyslipidosis.

Protein Name: TRNA Splicing Endonuclease Subunit 15

Functions: Non-catalytic subunit of the tRNA-splicing endonuclease complex, a complex responsible for identification and cleavage of the splice sites in pre-tRNA. It cleaves pre-tRNA at the 5' and 3' splice sites to release the intron. The products are an intron and two tRNA half-molecules bearing 2',3' cyclic phosphate and 5'-OH termini (PubMed:15109492, PubMed:27392077). There are no conserved sequences at the splice sites, but the intron is invariably located at the same site in the gene, placing the splice sites an invariant distance from the constant structural features of the tRNA body. The tRNA splicing endonuclease is also involved in mRNA processing via its association with pre-mRNA 3'-end processing factors, establishing a link between pre-tRNA splicing and pre-mRNA 3'-end formation, suggesting that the endonuclease subunits function in multiple RNA-processing events (PubMed:15109492)

The "TSEN15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TSEN15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets